MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer

Liu, Longyang; Yi, Jing; Deng, Xiaojie; Ji, Yuan; Zhou, Beixian; Lin, Zhongqiu; Zeng, Zhaoyang

doi:10.3892/ol.2019.10406

Cited by 24 publications

(27 citation statements)

References 20 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, down-regulating the MYH9 expression inhibited angiogenesis, migration, and invasion of esophageal cancer cells. Consistent with our research results, it was reported that expression of MYH9 is closely related to the malignant degree of cancer, and can be regarded as a marker for evaluating lymph node metastasis and poor prognosis in breast cancer [16], epithelial ovarian cancer [17] and acute myeloid leukemia [18]. Combined detection of vasculogenic mimicry, MYH9 and E-cad may play an essential role in predicting the invasion, metastasis, and progression of patients with ESCC [8,9].…”

Section: Discussionsupporting

confidence: 88%

MYH9 promotes cell metastasis via inducing Angiogenesis and Epithelial Mesenchymal Transition in Esophageal Squamous Cell Carcinoma

Yang¹,

Liu²,

Bi³

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

Non-muscle myosin heavy chain 9 (MYH9) is one novel low frequency mutated gene identified in esophageal squamous cell carcinoma (ESCC) using next-generation sequencing. However, its clinical relevance, potential function and mechanisms remain elusive. Methods: Genomic sequencing datas from 104 esophageal squamous cell carcinoma (ESCC) cases were screened a series of low frequency mutant genes. MYH9 was selected to further analyze its clinical significance, function and PCR-array was performed to explore its potential mechanism. Results: MHY9 is a low frequency mutant gene with a mutation frequency of 2.88% in ESCC. Immunohistochemical analysis showed that MYH9 expression was significantly higher in ESCC tumor tissues, and the expression levels were associated with lymph node metastasis of ESCC patients. Moreover, we found that MYH9 knock-down led to inhibition of cell migration and invasion. PCR-array showed MYH9 knockdown led to a significant change of genes expression associated with angiogenesis and epithelial-to-mesenchymal transition (EMT). This observation is further confirmed in TCGA database of LUSC (lung squamous cell carcinoma), CESC (cervical squamous cell carcinomas) and HNSC (head and neck squamous cell carcinoma). Conclusions: Collectively, our study identifies a novel role and mechanism of MYH9, highlights a significance of MYH9 as a metastatic biomarker, and offers potential therapeutic targets for ESCC patients harboring MYH9 mutations.

show abstract

Section: Discussionsupporting

confidence: 88%

MYH9 promotes cell metastasis via inducing Angiogenesis and Epithelial Mesenchymal Transition in Esophageal Squamous Cell Carcinoma

Yang¹,

Liu²,

Bi³

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Among the proteins associated with FNDC3B, MYH9 had the highest interaction score and was selected for further analysis (data not shown). MYH9 has been reported to function as an oncogene in most types of cancer, and it plays an important role in tumor cell adhesion, migration, and proliferation 18‐20 . The exogenous and endogenous coimmunoprecipitation showed that FNDC3B could physically interact with MYH9 (Figure 4B), which was verified by the immunofluorescence staining that FNDC3B was colocalized with MYH9 in the cytoplasm of both SUNE‐1 and HNE‐1 cells (Figure 4C).…”

Section: Resultsmentioning

confidence: 68%

“…As a skeleton protein, MYH9 plays an important role in cell adhesion, polarity, migration, and proliferation through mediating the actin‐based contractile motion 32 . MYH9 is recognized as an oncogene, as it is closely related to the progress and poor prognosis of most solid tumors 18‐20 . For example, MYH9 overexpression was induced by LIM kinase 1 (LIMK1) and promoted growth and metastasis by activating MAPK/AKT signaling in colorectal cancer 33,34 .…”

Section: Discussionmentioning

confidence: 99%

FNDC3B 3′‐UTR shortening escapes from microRNA‐mediated gene repression and promotes nasopharyngeal carcinoma progression

Yang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

Alternative polyadenylation (APA), which induces shortening of the 3′‐UTR, is emerging as an important feature in cancer development and progression. Nevertheless, the effects and mechanisms of APA‐induced 3′‐UTR shortening in nasopharyngeal carcinoma (NPC) remain largely unclear. Fibronectin type III domain containing 3B (FNDC3B) tended to use proximal polyadenylation site and produce shorter 3′‐UTR according to our previous sequencing study. Herein, we found that FNDC3B with shorter 3′‐UTR could escape from miRNA‐mediated gene repression, and caused its increased expression in NPC. Knocking down of FNDC3B inhibited NPC cell proliferation, migration, invasion, and metastasis in vitro and in vivo. Overexpression of FNDC3B, especially those with shorter 3′‐UTR, promoted NPC progression. Furthermore, the mechanism study revealed that FNDC3B could bind to and stabilize myosin heavy chain 9 (MYH9) to activate the Wnt/β‐catenin signaling pathway. In addition, MYH9 could reverse the inhibitory effects of FNDC3B knockdown in NPC. Altogether, our results suggested that the 3′‐UTR shortening of FNDC3B mRNA mediated its overexpression in NPC and promoted NPC progression by targeting MYH9. This newly identified FNDC3B‐MYH9‐Wnt/β‐catenin axis could represent potential targets for individualized treatment in NPC.

show abstract

“…Further, robust prognostic markers to monitor the outcome of patient treatment are also lacking. Currently, CA125 and HE4 are suggested as prognostic biomarkers for ovarian cancer, however they lack specificity and sensitivity in monitoring disease progress [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer

et al. 2021

View full text Add to dashboard Cite

Background High grade serous ovarian cancer (HGSOC) accounts for nearly 60% of total cases of epithelial ovarian cancer. It is the most aggressive subtype, which shows poor prognosis and low patient survival. For better management of HGSOC patients, new prognostic biomarkers are required to facilitate improved treatment strategies and ensure suitable healthcare decisions. Methods We performed genome wide expression analysis of HGSOC patient samples to identify differentially expressed genes (DEGs) using R based Limma package, Clust and other statistical tools. The identified DEGs were subjected to weighted gene co-expression network analysis (WGCNA) to identify co-expression patterns of relevant genes. Module trait and gene ontology analyses were performed to establish important gene co-expression networks and their biological functions. Overlapping the most relevant DEG cluster 4 with prominent WGCNA cyan module identified strongest correlation of UBE2Q1 with ovarian cancer and its prognostic significance on survival probability of ovarian cancer patients was investigated. The predictive value of UBE2Q1 as a potential biomarker was analysed by correlating its expression with 12-months relapse free survival of patients in response to platin/taxane, the standard first-line chemotherapy for ovarian cancer, and analysing area under the ROC curve. Results An integrated gene expression analysis and WGCNA, identified UBE2Q1 as a potential prognostic marker associated with poor relapse-free survival and response outcome to platin/taxane treatment of patients with high grade serous ovarian cancer. Conclusions Our study identifies a potential UBE2Q1 – B4GALT3 functional axis in ovarian cancer, where only the E2 conjugating enzyme showed a poor prognostic impact on the disease.

show abstract

MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer

Cited by 24 publications

References 20 publications

MYH9 promotes cell metastasis via inducing Angiogenesis and Epithelial Mesenchymal Transition in Esophageal Squamous Cell Carcinoma

MYH9 promotes cell metastasis via inducing Angiogenesis and Epithelial Mesenchymal Transition in Esophageal Squamous Cell Carcinoma

FNDC3B 3′‐UTR shortening escapes from microRNA‐mediated gene repression and promotes nasopharyngeal carcinoma progression

Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer

Contact Info

Product

Resources

About